{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:25:56Z","timestamp":1769826356802,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00259-023-06463-2","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:01:21Z","timestamp":1697428881000},"page":"820-827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7767-0393","authenticated-orcid":false,"given":"H.","family":"Siebinga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M. V.","family":"de Vries-Huizing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"de Wit-van der Veen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"issue":"2","key":"6463_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"16","key":"6463_CR2","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.Ccr-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0), Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2743.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6463_CR3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00432-020-03181-2","volume":"146","author":"J Zhang","year":"2020","unstructured":"Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of (177)Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146(6):1533\u201343. https:\/\/doi.org\/10.1007\/s00432-020-03181-2.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"13","key":"6463_CR4","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","volume":"45","author":"M Cremonesi","year":"2018","unstructured":"Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to (90)Y- and (177)Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45(13):2426\u201341. https:\/\/doi.org\/10.1007\/s00259-018-4044-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6463_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.semnuclmed.2015.12.003","volume":"46","author":"L Bodei","year":"2016","unstructured":"Bodei L, Kwekkeboom DJ, Kidd M, Modlin IM, Krenning EP. Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer. Semin Nucl Med. 2016;46(3):225\u201338. https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.12.003.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"6463_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2967\/jnumed.112.107524","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, Garske-Rom\u00e1n U, Granberg D, Johansson S, Widstr\u00f6m C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33\u201341. https:\/\/doi.org\/10.2967\/jnumed.112.107524.","journal-title":"J Nucl Med"},{"issue":"11","key":"6463_CR7","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","volume":"49","author":"A Sundl\u00f6v","year":"2022","unstructured":"Sundl\u00f6v A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830\u201340. https:\/\/doi.org\/10.1007\/s00259-022-05786-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6463_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, et al. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728\u201342. https:\/\/doi.org\/10.1007\/s00259-018-4209-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6463_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","volume":"13","author":"S Das","year":"2019","unstructured":"Das S, Al-Toubah T, El-Haddad G, Strosberg J. (177)Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019;13(11):1023\u201331. https:\/\/doi.org\/10.1080\/17474124.2019.1685381.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4 Suppl","key":"6463_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cncr.24796","volume":"116","author":"M Garkavij","year":"2010","unstructured":"Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084\u201392. https:\/\/doi.org\/10.1002\/cncr.24796.","journal-title":"Cancer"},{"issue":"5","key":"6463_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/cancers13050962","volume":"13","author":"U Jahn","year":"2021","unstructured":"Jahn U, Ilan E, Sandstr\u00f6m M, Lubberink M, Garske-Rom\u00e1n U, Sundin A. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE; Differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms. Cancers. 2021;13(5):962.","journal-title":"Cancers"},{"issue":"3","key":"6463_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2967\/jnumed.121.262069","volume":"63","author":"D Roth","year":"2022","unstructured":"Roth D, Gustafsson J, Warfvinge CF, Sundl\u00f6v A, \u00c5kesson A, Tennvall J, et al. Dosimetric quantities in neuroendocrine tumors over treatment cycles with (177)Lu-DOTATATE. J Nucl Med. 2022;63(3):399\u2013405. https:\/\/doi.org\/10.2967\/jnumed.121.262069.","journal-title":"J Nucl Med"},{"issue":"1","key":"6463_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40658-020-00308-9","volume":"7","author":"DMV Huizing","year":"2020","unstructured":"Huizing DMV, Peters SMB, Versleijen MWJ, Martens E, Verheij M, Sinaasappel M, et al. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys. 2020;7(1):36. https:\/\/doi.org\/10.1186\/s40658-020-00308-9.","journal-title":"EJNMMI Phys"},{"issue":"5","key":"6463_CR14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00259-022-06094-z","volume":"50","author":"C Veerman","year":"2023","unstructured":"Veerman C, Siebinga H, de Vries-Huizing DMV, Tesselaar MET, Hendrikx J, Stokkel MPM, et al. The effect of long-acting somatostatin analogues on the uptake of [(177)Lu]Lu-HA-DOTATATE. Eur J Nucl Med Mol Imaging. 2023;50(5):1434\u201341. https:\/\/doi.org\/10.1007\/s00259-022-06094-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"6463_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/psp4.12914","volume":"12","author":"H Siebinga","year":"2023","unstructured":"Siebinga H, Priv\u00e9 BM, Peters SMB, Nagarajah J, Dorlo TPC, Huitema ADR, et al. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of (177) Lu-PSMA-617 in prostate cancer patients. CPT Pharmacometrics Syst Pharmacol. 2023;12(8):1060\u201371. https:\/\/doi.org\/10.1002\/psp4.12914.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"6463_CR16","doi-asserted-by":"crossref","unstructured":"ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. Ann ICRP. 2002;32(3\u20134):5\u2013265.","DOI":"10.1016\/S0146-6453(03)00002-2"},{"issue":"2","key":"6463_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s40262-018-0674-1","volume":"58","author":"A Puszkiel","year":"2019","unstructured":"Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E. Evaluation of the interaction of amino acid infusion on (177)Lu-dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors. Clin Pharmacokinet. 2019;58(2):213\u201322. https:\/\/doi.org\/10.1007\/s40262-018-0674-1.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"6463_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/aln.0000000000004115","volume":"136","author":"DJ Eleveld","year":"2022","unstructured":"Eleveld DJ, Koomen JV, Absalom AR, Su H, Hannivoort LN, Struys M. Allometric scaling in pharmacokinetic studies in anesthesiology. Anesthesiology. 2022;136(4):609\u201317. https:\/\/doi.org\/10.1097\/aln.0000000000004115.","journal-title":"Anesthesiology"},{"issue":"2","key":"6463_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"issue":"1","key":"6463_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28\u201347. https:\/\/doi.org\/10.1210\/er.2000-0001.","journal-title":"Endocr Rev"},{"issue":"2","key":"6463_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12022-020-09623-4","volume":"31","author":"M Schiavo Lena","year":"2020","unstructured":"Schiavo Lena M, Partelli S, Castelli P, Andreasi V, Smart CE, Pisa E, et al. Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT). Endocr Pathol. 2020;31(2):119\u201331. https:\/\/doi.org\/10.1007\/s12022-020-09623-4.","journal-title":"Endocr Pathol"},{"issue":"13","key":"6463_CR22","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/jco.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330. https:\/\/doi.org\/10.1200\/jco.2007.15.2553.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6463_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/acm2.12991","volume":"21","author":"DMV Huizing","year":"2020","unstructured":"Huizing DMV, Sinaasappel M, Dekker MC, Stokkel MPM, de Wit-vander Veen BJ. (177) Lutetium SPECT\/CT: evaluation of collimator, photopeak and scatter correction. J Appl Clin Med Phys. 2020;21(9):272\u20137. https:\/\/doi.org\/10.1002\/acm2.12991.","journal-title":"J Appl Clin Med Phys"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06463-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06463-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T21:29:51Z","timestamp":1705613391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06463-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6463"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06463-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. The study was approved by the Institutional Review Board of the Netherlands Cancer Institute in Amsterdam, the Netherlands (IRBd21-187).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained via institutional procedures from all individual participants included in the studies (of which data were used for model evaluation).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}